These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35492881)

  • 1. Precision medicine in pediatric severe asthma: Targeted blockade of type 2 inflammation.
    Larkin AS; Wenzel SE
    Cell Rep Med; 2022 Mar; 3(3):100570. PubMed ID: 35492881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs.
    Parulekar AD; Kao CC; Diamant Z; Hanania NA
    Curr Opin Pulm Med; 2018 Jan; 24(1):50-55. PubMed ID: 29036019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dupilumab in persistent asthma with elevated eosinophil levels.
    Wenzel S; Ford L; Pearlman D; Spector S; Sher L; Skobieranda F; Wang L; Kirkesseli S; Rocklin R; Bock B; Hamilton J; Ming JE; Radin A; Stahl N; Yancopoulos GD; Graham N; Pirozzi G
    N Engl J Med; 2013 Jun; 368(26):2455-66. PubMed ID: 23688323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized medicine in children with asthma.
    Pijnenburg MW; Szefler S
    Paediatr Respir Rev; 2015 Mar; 16(2):101-7. PubMed ID: 25458797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma.
    Corren J; Castro M; O'Riordan T; Hanania NA; Pavord ID; Quirce S; Chipps BE; Wenzel SE; Thangavelu K; Rice MS; Harel S; Jagerschmidt A; Khan AH; Kamat S; Maroni J; Rowe P; Lu Y; Amin N; Pirozzi G; Ruddy M; Graham NMH; Teper A
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):516-526. PubMed ID: 31521831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
    Castro M; Corren J; Pavord ID; Maspero J; Wenzel S; Rabe KF; Busse WW; Ford L; Sher L; FitzGerald JM; Katelaris C; Tohda Y; Zhang B; Staudinger H; Pirozzi G; Amin N; Ruddy M; Akinlade B; Khan A; Chao J; Martincova R; Graham NMH; Hamilton JD; Swanson BN; Stahl N; Yancopoulos GD; Teper A
    N Engl J Med; 2018 Jun; 378(26):2486-2496. PubMed ID: 29782217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe asthma: what is new in the new millennium.
    Ntontsi P; Samitas K; Zervas E; Gaga M
    Curr Opin Allergy Clin Immunol; 2020 Apr; 20(2):202-207. PubMed ID: 32004177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized Approach to Severe Asthma.
    Heffler E; Canonica GW; Diamant Z; Fonseca J; Malinovschi A
    Biomed Res Int; 2018; 2018():2465172. PubMed ID: 30671448
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical trial research in focus: do trials prepare us to deliver precision medicine in those with severe asthma?
    Brightling CE
    Lancet Respir Med; 2017 Feb; 5(2):92-95. PubMed ID: 28145230
    [No Abstract]   [Full Text] [Related]  

  • 10. Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis.
    Maspero JF; Katelaris CH; Busse WW; Castro M; Corren J; Chipps BE; Peters AT; Pavord ID; Ford LB; Sher L; Rabe KF; Rice MS; Rowe P; Lu Y; Harel S; Jagerschmidt A; Khan AH; Kamat S; Pirozzi G; Amin N; Ruddy M; Graham NMH; Mannent LP; Teper A
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):527-539.e9. PubMed ID: 31351189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotype-Driven Therapeutics in Severe Asthma.
    Opina MT; Moore WC
    Curr Allergy Asthma Rep; 2017 Feb; 17(2):10. PubMed ID: 28233153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted anti-IL-13 therapies in asthma: current data and future perspectives.
    Ntontsi P; Papathanassiou E; Loukides S; Bakakos P; Hillas G
    Expert Opin Investig Drugs; 2018 Feb; 27(2):179-186. PubMed ID: 29334288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.
    Wechsler ME; Ford LB; Maspero JF; Pavord ID; Papi A; Bourdin A; Watz H; Castro M; Nenasheva NM; Tohda Y; Langton D; Cardona G; Domingo C; Park HS; Chapman KR; Mao X; Zhang Y; Khan AH; Deniz Y; Rowe PJ; Kapoor U; Khokhar FA; Mannent LP; Ruddy M; Laws E; Amin N; Hardin M
    Lancet Respir Med; 2022 Jan; 10(1):11-25. PubMed ID: 34597534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asthma exacerbations during pregnancy: A need for precision medicine.
    Brightling CE
    Respirology; 2020 Jul; 25(7):670-671. PubMed ID: 31840898
    [No Abstract]   [Full Text] [Related]  

  • 15. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
    Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma.
    Corren J; Katelaris CH; Castro M; Maspero JF; Ford LB; Halpin DMG; Rice MS; Radwan A; Deniz Y; Rowe PJ; Teper A; Djandji M
    Eur Respir J; 2021 Oct; 58(4):. PubMed ID: 34266940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision medicine in asthma: linking phenotypes to targeted treatments.
    Chung KF
    Curr Opin Pulm Med; 2018 Jan; 24(1):4-10. PubMed ID: 29036018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances toward precision medicine for asthma.
    Louis R; Bureau F; Desmet CJ
    Biochem Pharmacol; 2020 Sep; 179():114081. PubMed ID: 32511986
    [No Abstract]   [Full Text] [Related]  

  • 19. Choosing the right biologic for severe asthma: precision medicine through the lens of patient-centered decision making.
    Desai M; Oppenheimer J
    Ann Allergy Asthma Immunol; 2019 Oct; 123(4):331-332. PubMed ID: 31351166
    [No Abstract]   [Full Text] [Related]  

  • 20. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.
    Godar M; Blanchetot C; de Haard H; Lambrecht BN; Brusselle G
    MAbs; 2018 Jan; 10(1):34-45. PubMed ID: 29035619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.